# A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Study · id `cardio:ct-nct05610280` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05610280](<https://clinicaltrials.gov/study/NCT05610280>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05610280

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1478 participants.

## Technical summary

Registry record NCT05610280. Randomized; quadruple masking; primary purpose treatment. Start 2022-11-21 (actual); primary completion 2024-08-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1478 participants (enrolled count; ClinicalTrials.gov record NCT05610280, source copy `cardio:ctgov-nct05610280-2026-02-10`, retrieved 2026-10-31)
- Started: 2022-11-21 (actual) (ClinicalTrials.gov record NCT05610280, source copy `cardio:ctgov-nct05610280-2026-02-10`, retrieved 2026-10-31)
- Primary completion: 2024-08-08 (actual) (ClinicalTrials.gov record NCT05610280, source copy `cardio:ctgov-nct05610280-2026-02-10`, retrieved 2026-10-31)
- Completion: 2025-06-09 (actual) (ClinicalTrials.gov record NCT05610280, source copy `cardio:ctgov-nct05610280-2026-02-10`, retrieved 2026-10-31)
- Countries: United States; Bulgaria; Canada; Czechia; Denmark; France; Hungary; Italy; Netherlands; Norway; Poland; Portugal; Slovakia; Spain (ClinicalTrials.gov record NCT05610280, source copy `cardio:ctgov-nct05610280-2026-02-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05610280-2026-02-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
- Condition: Hypertriglyceridemia
- Condition: Cardiovascular Diseases
- Condition: Atherosclerosis
- Intervention (Drug): Olezarsen
- Intervention (Drug): Placebo
- Lead sponsor: Ionis Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: Ionis Pharmaceuticals, Inc. (`cardio:org-ionis-pharmaceuticals-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia (`cardio:pubmed-40888739`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study (`cardio:pubmed-41910513`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5cfeb6a725fc083e98cb0b4502386efcb84fe30ee3a2918521e0138588ed082c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
